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Summary Infantile haemangioma (IH) is the most common tumour during early childhood.
Although these benign lesions resolve spontaneously, up until recently laryngotracheal sites
of IH required invasive management. The dramatic efﬁcacy of -blockers on IH has radicallyChild;
Upper airways;
Propranolol;
-blockers
changed the prognosis. Surgery is now no longer indicated as ﬁrst-line therapy, but should only
be performed for difﬁcult, refractory cases, or in the presence of absolute contraindications to
-blockers. Long-term steroid therapy is also no longer indicated. Propranolol can be used as
ﬁrst-line, single-agent therapy.
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nfantile haemangioma (IH), in all sites, is the most com-
on tumour in children. Despite its benign nature and its
pontaneously favourable course, IH can sometimes be asso-
iated with a severe functional (labial or palpebral sites),
osmetic (thoracic site in young women), and vital prognosis
bleeding, respiratory tract involvement).
Paediatric ENT surgeons are mainly concerned by laryngo-
racheal haemangiomas. Up until recently, IH of the airways
equired complex and/or invasive treatments, sometimes
ssociated with temporary tracheotomy.
The dramatic efﬁcacy of propranolol (and -blockers in
eneral) on infantile haemangiomas, described for the ﬁrst
ime in 2008 by a French team, has radically changed the
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rognosis of these lesions, requiring revision of the previ-
usly accepted therapeutic indications [1].
nfantile haemangioma
H is a benign vascular tumour, rather than a vascular mal-
ormation. It has a characteristic histological appearance
typical capillary proliferation) and a speciﬁc marker is asso-
iated with this tumour: GLUT-1 [2].
IH affects 4 to 10% of infants under the age of one year,
nd up to 30% of low birthweight preterm infants (less than
,500 g) [3]. This tumour is more frequent in girls, especially
n the context of certain syndromes (PHACES syndrome) [4].
ther risk factors have also been identiﬁed: white skin, and
ntenatal or perinatal hypoxia, especially in the presence of
lacental abnormalities [5].
The lesion is typically discovered at birth or soon after
irth, then rapidly increases in volume during the ﬁrst year
f life, sometimes until the age of 18months. It then slowly,
ut constantly decreases in size. The very great major-
ty of lesions have resolved by the age of 7 years, possibly
served.
Infantile haemangioma and -blockers in otolaryngology 237
Figure 1 Endoscopic view of the larynx. Glottic (medial edge F
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IH, predominantly situated on the head [60% of cases] and
prominences, representing possible pressure points during
the antenatal and perinatal periods). This hypoxic stressof the posterior half of the right cord) and posterior subglottic
haemangioma.
leaving only minor cosmetic sequelae: distended skin zones
or ﬁbroadipose residues [6]. Prior to the introduction of pro-
pranolol, the severe complication rate was estimated to be
10% [7].
IH is the most common tumour of the airway in children.
Subglottic lesions are generally responsible for rapid onset
of clinical features, as, according to Poiseuille’s law, resis-
tance to ﬂow of a liquid in a pipe is equal to the radius
raised to the fourth power. This means that if the radius
of the airways is decreased by one half, airﬂow resistance,
and therefore the effort required to maintain satisfactory
ventilation, increase 16-fold. The subglottic region, physi-
ologically the narrowest segment of the upper airways, is
therefore the most likely to be the site of clinical symptoms
related to an angiomatous lesion of the airway. The diag-
nosis is established on complete endoscopy of the airway
(Figs. 1 and 2). MRI can be useful to deﬁne the extent of
very large lesions (Fig. 3).
Prior to the introduction of -blockers, medical treat-
ment was based on corticosteroids (systemic or topical),
vincristine, and interferon, all of which have potentially
serious adverse effects. Surgery was performed either via
an open approach or by endoscopy (laser). Tracheotomy was
required in the most severe cases, despite the higher mor-
bidity and mortality of this procedure in children than in
adults [7].
Beta-blockers
Beta-blockers are antagonists of the -adrenergic effects of
catecholamines, with multiple systemic effects (decreased
cardiac output, bronchoconstriction, decreased insulin
secretion). Most are fat-soluble and have a very good
bioavailability. They have been used in therapeutics in chil-
dren and adults, essentially in cardiology, for more than
50 years [8].
F
rigure 2 Same patient, rigid 0◦ 4mm tracheoscopy: very
arge right posterior IH (*) causing about 80% obstruction.
The efﬁcacy of propranolol on cutaneous IH was discov-
red incidentally in 2008 [1,9] and the ﬁrst case of successful
reatment of laryngotracheal haemangioma was reported
he following year [10].
The mechanisms of action of -blockers on IH have
ot been fully elucidated. IH is currently thought to be
he consequence of pathological neoangiogenesis in reac-
ion to ischaemia of a skin territory during foetal life
systemic ischaemia would explain segmental IH, while
ocalized ischaemia would be responsible for circumscribedigure 3 Same patient, cervical MRI, T2-weighted sequence:
ight posterior tracheal IH with high-intensity signal (arrow).
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Table 1 Published reports of cases of IH of the airways treated by -blockers.
Authors Year Number of
patients
-blocker Dosage
(mg/kg/day)
Denoyelle et al. [10] 2009 3 Propranolol 2—3
Buckmiller [23] 2009 1 Propranolol 2
Jephson et al. [18] 2009 1 Propranolol 2
Mistry and Tzifa [24] 2010 1 Propranolol 2
Rosbe et al. [25] 2010 3 Propranolol 1—2
Truong et al. [19] 2010 6 Propranolol 2
Truong et al. [26] 2010 1 Propranolol 2
Maturo and Hartnick [27] 2010 2 Propranolol 2
Blanchet et al. [17] 2010 3 Acebutolol 8
Canadas et al. [15] 2010 1 Propranolol 2
Leboulanger et al. [14] 2010 14 Propranolol + Acebutolol 2—3
would induce the release of pro-angiogenic factors (VEGF,
bFGF, etc.) stimulating the proliferation of an endothelial
cell clone and resulting in the formation of an IH. Beta-
blockers appear to act by inhibiting the secretion of these
factors, which stops pathological cell proliferation, and also
induces forced apoptosis [5,11—13].
In practice, the efﬁcacy of propranolol on IH is spectacu-
lar, as regression of the tumour may sometimes be observed
within a few hours after the ﬁrst dose [1].
Review of the literature and current
indications
Efﬁcacy of -blockers
Many articles reporting the efﬁcacy of -blockers on laryngo-
tracheal IH have been published since 2009: about 40 cases
Figure 4 Endoscopic view of the subglottic region of a 4-
month-old female infant with a very large left posterolateral
subglottic IH, causing almost 90% obstruction.
have been reported (Table 1). The response to treatment,
evaluated by clinical examination and especially endoscopic
assessment, is rapid and signiﬁcant (Figs. 4 and 5) [14].
Two treatment-refractory cases in these sites have been
reported to date [14,15], including one case after pre-
mature discontinuation of treatment. These two patients
were subsequently treated by conventional surgical resec-
tion. Although it is too early to determine precise ﬁgures,
-blockers are considered to be very effective on laryngo-
tracheal IH, but adverse effects of treatment are not rare
(at least ﬁve out of 40 cases) although benign.
Precautions for use
The protocol of introduction of -blockers in children with
IH was rapidly deﬁned [9]. It consists of looking for any
contraindications to treatment (cardiac conduction block,
Figure 5 Endoscopic view of the subglottic region; same
patient as in Fig. 4: appearance of the lesion after 2weeks of
treatment with propranolol. Residual obstruction estimated to
be 20%.
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ventricular failure, etc.) and detecting any early adverse
effects. There is no minimum age for initiation of treatment,
but hospitalisation for several days is justiﬁed in infants with
sometimes severely obstructive lesions. A paediatric cardi-
ology consultation, ECG and echocardiography are required
before starting treatment.
Treatment is initiated at a low dose, in three divided
doses per day. The starting dosage is usually 0.5mg/kg per
day in three divided doses, but can be increased to 1mg/kg
per day after 48 hours when treatment is well tolerated
(surveillance of heart rate, blood pressure, and capillary
blood glucose because of the risk of hypoglycaemia) [16].
The dosage is adjusted by steps of 0.5 to 1mg/kg every
48 hours, as the effective dose is generally situated between
2 and 3mg/kg per day in three divided doses. An oral suspen-
sion form of propranolol, adapted to children, is currently
being developed for the French market and should be avail-
able soon.
Bronchospasm is generally only observed in children with
pre-existing bronchial hyperreactivity [9]. However, a car-
dioselective -blocker (acebutolol) can be used, while the
concomitant use of inhaled bronchodilators should be lim-
ited to patients in whom they are absolutely necessary [17].
Dose and duration of treatment
The effective dose is generally situated between 2 and
3mg/kg per day in three divided doses. In refractory cases,
the dosage can be increased to 4mg/kg per day in three
divided doses. Most authors recommend maintenance of
treatment until the end of the IH growth period, i.e. at least
until the age of one year for some authors, and until the
age of 18months for most authors, as relapses after prema-
ture discontinuation of treatment and cases of secondary
resistance have been described [14,15].
Current indications
Although the series published to date are only descriptive
case reports, the superiority of -blockers for the treat-
ment of IH of the upper airways is now generally accepted.
To date, about 30 patients treated by -blockers alone
have been reported in the literature, with excellent results
[14,18—20].
Beta-blockers are now indicated as ﬁrst-line treatment
for IH in children, with the following exceptions:
• very rare formal contraindications to -blockers, in which
conventional treatment should be preferred;
• small, unilateral, isolated, minimally active subglottic
angiomas, in which the beneﬁt—risk ratio of a single endo-
scopic procedure must be weighed up against that of drug
treatment for several months.
A short course of high-dose corticosteroid therapy can
be considered in patients with severe respiratory signs,
until -blocker therapy becomes effective. Finally, endo-
scopic or open surgery may be indicated in acute situations
(emergency disobstruction) or to treat cases refractory to
-blockers [20—22].
[239
ropranolol or acebutolol
ery few patients have been treated to date with acebutolol
lone, but with good results [17]. As this molecule, with
ewer peripheral effects, should theoretically induce fewer
dverse effects than propranolol, it could possibly be pre-
erred as ﬁrst-line treatment. Nevertheless, rigorous clinical
rials are necessary to compare the respective efﬁcacy of
hese two molecules.
onclusion
ropranolol has transformed the prognosis and management
f laryngotracheal IH. Surgery no longer appears to be jus-
iﬁed as ﬁrst-line treatment, but should be reserved for
ifﬁcult, refractory cases, or in the case of absolute con-
raindications to all -blockers. Long-term corticosteroid
herapy and prolonged treatment with interferon or vin-
ristine are clearly a thing of the past. Although practice
uidelines are still incomplete, the use of -blockers has
onsiderably simpliﬁed the therapeutic management of
aryngotracheal IH.
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